Hostile Biotech
Executive Summary
In this era of hostile pharmaceutical acquisitions perhaps the most attractive candidate is Amgen.
In this era of hostile pharmaceutical acquisitions, perhaps the most attractive candidate is Amgen. Epogenand especially Neupogen seem to have inexhaustible growth prospects (especially with the possibility of Neupogen winning an anti-infective claim). Says one executive who has run the numbers but whose company isn’t big enough to take advantage of the opportunity: “We believe Amgen can be run with about 500 people [the company now employs 3352]. And could throw off about $1 billion per year in cash.”